Clinical Trial Detail

NCT ID NCT03141671
Title Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

prostate cancer

Therapies

Bicalutamide + Gonadorelin

Abiraterone + Apalutamide + Gonadorelin + Prednisone

Age Groups: adult senior

No variant requirements are available.